Clinical Trial News Archive
Get news by email or subscribe to our news feeds.
News Archive for July 2011
July 1, 2011
- Ataluren Phase 2 Data in Nonsense Mutation Cystic Fibrosis Published in the European Respiratory Journal
- Alkermes Announces Positive Results from Clinical Study of ALKS 9070 For Treatment of Schizophrenia
- miRagen Therapeutics and Collaborators Identify Key Role for miR-133a as a Modulator of Skeletal Muscle Disorder
July 5, 2011
- ARIAD Announces Presentation on Its Investigational Lung Cancer Drug Candidate, AP26113, a Dual Inhibitor of ALK and EGFR, at World Conference on Lung Cancer
- Novartis Drug Afinitor Met Primary Endpoint of Phase III Study in Women With Advanced Breast Cancer; Potential to Address Significant Unmet Need
- Exposure to Antidepressants in Early Pregnancy May Increase the Risk of Autism Spectrum Disorders
July 6, 2011
- Oncolytics Biotech Inc. Collaborators Present Positive REOLYSIN Clinical Trial Results at the 14th World Conference on Lung Cancer
- Synta Announces Presentation of Small Cell Lung Cancer Results at IASLC 14th World Conference on Lung Cancer
- Positive Top-Line Results For Pfizer's Lyrica In Phase 3 Study Of Patients With Fibromyalgia In Japan
July 7, 2011
- Palonosetron Better Prevents Nausea and Vomiting Linked to High Emetogenic Chemotherapy Lung Cancer Patients
- Alkermes Announces Results from Phase 2 Study of ALKS 33 for Treatment of Binge Eating Disorder
- Idera Pharmaceuticals Provides Update on IMO-2055 Clinical Development Program
- Behavioral Treatment for Migranes a Cost-effective Alternative to Meds, Study Finds
- Combination Therapy as Good as Old Regimen to Prevent Full-blown TB in People with/without HIV
- Drug 'shield' Helps Target Antibiotic Resistant Bacteria
- Synta Announces Presentation of Ganetespib Phase 2 Non-small Cell Lung Cancer Trial Results at IASLC 14th World Conference on Lung Cancer
- Exelixis Provides Update on Cabozantinib Development Activities
July 8, 2011
- Phase III Trial of Novartis Drug Afinitor Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis
- Exenatide tQT Study Showed No Prolongation of QT Interval
- Generex Provides Preliminary Results of Generex Oral-lyn Clinical Trials in Patients with Type 1 Diabetes and Patients with Impaired Glucose Tolerance
- Nuvilex Announces Successful Breast Cancer Preclinical Studies
- Baxter and Halozyme Announce Top-Line Results of Phase III Study of HyQ in Patients with Primary Immunodeficiency
- New Study Confirms Role of Environment in the Development of Autism
- Seaside Therapeutics Presents Data on Potential Pharmaceutical Treatment for Improving Social Impairment in Autism Spectrum Disorders at 42nd Autism Society National Conference
July 11, 2011
- iBio Announces Plasma Protein Development on its iBioLaunch Platform
- Sanofi Reports Positive Top-Line Results from First Phase 3 Study of Alemtuzumab (Lemtrada) in Multiple Sclerosis
- Phase Two Study Suggests Use of Adult Autologous Stem Cells May Improve Cardiac Function in Angina Patients
- Sunshine Biopharma's Adva-27a is 16-times more effective at killing multidrug resistant breast cancer cells
- Generex Announces Publication of Studies with the Mayo Clinic Confirming and Extending the Antigen Express Ii-Key Platform Technology
- Metabolon Research into Dietary Leucine Published in PLoS One
- Cream In Vitro Data Demonstrates Activity Against Head Lice Eggs
- Study May Lead to Improved Treatment for Lung Disease
- Vitamin D insufficiency prevalent among psoriatic arthritis suffers
July 12, 2011
July 13, 2011
- AVAC Says Results of New PrEP Trials Provide Clear Evidence that Antiretroviral Drugs for Prevention Can Help End the AIDS Epidemic; Calls for Quick Action to Move Landmark HIV Prevention Results Toward Lifesaving Programs
- Genfit: The Gft505-210-5 Clinical Trial Confirms the Broad Spectrum of Action of Gft505 in Diabetic Patients
- Arena Pharmaceuticals Announces Phase 1 Results for APD811 for Pulmonary Arterial Hypertension
- Celprogen Announces Development of Neuronal Stem Cells Derived from Adult Human Brains; May Someday Be an Effective Therapy for Alzheimer's Patients
- CYTAVIS? Aviscumine Improves Survival of Patients with Metastatic Melanoma in a Phase II Trial Hamburg
- Sanofi and Regeneron Report Positive Phase 2b Trial Results with Sarilumab in Rheumatoid Arthritis
- Epizyme and Collaborators Publish Paper in Cancer Cell Supporting Use of DOT1L Histone Methyltransferase Inhibitors as Personalized Therapeutics for Genetically-Defined MLL-rearranged Leukemia Patients
July 14, 2011
- Long-term NSAID Use by Hypertensive Patients with CAD Increases Risk of Adverse Events
- Landmark Study Finds Antiretroviral Drugs Highly Effective at Preventing HIV in Both Men and Women
- Pivotal Study In Africa Finds That HIV Medications Prevent HIV Infection
July 15, 2011
- Inovio Pharmaceuticals Demonstrates T Cell Immune Response Durability with Fourth Dose of Therapeutic Cervical Dysplasia and Cancer DNA Vaccine
- Anavex to present at Alzheimer's Association International Conference on Alzheimer's Disease
- Pertuzumab Combined With Herceptin and Chemotherapy Significantly Extended the Time People With HER2-Positive Metastatic Breast Cancer Lived Without Their Disease Getting Worse
July 18, 2011
- Aeterna Zentaris Announces Poster Presentation on Final Phase 2 Results for AEZS-108 in Endometrial Cancer at Upcoming European Society of Gynaecological Oncology Meeting
- EpiCept Corporation Announces Publication in journal Blood of a New Meta-Analysis Examining Lack of Efficacy of Interleukin-2 as Monotherapy in AML Remission Maintenance
- Forest Laboratories, Inc. and Pierre Fabre Medicament Announce Positive Phase III Results with Levomilnacipran in Patients with Major Depressive Disorder
- New Data Showed Minimal Potential for Drug Interaction Between Cholesterol Drug LIVALO and a Common Antiretroviral Therapy
- Merck's ISENTRESS (raltegravir) in Combination Therapy Demonstrated Efficacy in a Phase II Study Extending to Nearly Five Years in Previously Untreated Adults with HIV-1
- Nabi Biopharmaceuticals Announces Results of First NicVAX Phase III Clinical Trial
- Scientists Use Live Bacteria to Fight HIV
July 19, 2011
- New Global Model of Alzheimer's Risk Suggests a 25 Percent Reduction in Presumed Risk Factors Could Lower Alzheimer's Cases by 3 Million Worldwide
- Tobira Therapeutics Presents Pharmacokinetics and Safety Data that Support Coadministration of Cenicriviroc with Tenofovir DF in Healthy Adults
- Lilly Presents Follow-Up Data on Semagacestat to Assist Future Alzheimer's Disease Research
- Alnylam and MIT Collaborators Publish Data on Novel Lipid Nanoparticles for Systemic Delivery of RNAi Therapeutics
- EDURANT 96-Week Phase 3 Safety and Efficacy Data Presented at International AIDS Society Conference
- American Heart Association Rapid Access Journal Report: Experimental Drug Raises "Good" Cholesterol, May Help Control Diabetes
July 20, 2011
- ViroStatics CEO, Franco Lori, MD, Presents Late Breaker on Novel AV-HALT HIV Therapy at the 2011 International AIDS Society Pathogenesis Conference
- Pharmasset Announces Final SVR Data from PROTON trial with PSI-7977 in Subjects Infected with Hepatitis C Infection Genotype 2 or 3
- New Use for an Old Drug: Chloroquine Finding May Lead to Treatments for Arthritis, Cancer, and Other Diseases
- DMRF-Supported Investigators Close In On Function of Protein Associated with Dystonia
- NanoBio Announces Publication of Study Results For Intranasal Nanoemulsion-Adjuvanted Vaccine
- As New Data Wave Begins, a Gene Study in One Disease Discovers Mutations in an Unrelated Disease
- Evolva completes Phase I studies with EV-077
- Dynavax Phase 3 Demonstrates Superiority and Safety of HEPLISAV vs. Engerix-B
July 21, 2011
- Vical Reports Successful Nonclinical Results With Vaxfectin Adjuvant
- Gilead's Investigational Antiretroviral Elvitegravir Once Daily Non-Inferior to Raltegravir Twice Daily at 48 Weeks
- Virginia G. Piper Cancer Center, TGen Studying New Breast Cancer Drug
- Data on Bristol-Myers Squibb's Investigational Treatment for Alzheimer's Disease Demonstrate Potential Therapeutic Window at Doses Below 100 mg in Phase II Safety and Tolerability Study
- Adamis Reports APC-300 Kills Human Prostate Cancer Cells
July 22, 2011
- Signaling Molecule Identified as Essential for Maintaining a Balanced Immune Response
- MS Research: Myelin Influences How Brain Cells and Send Signals
- Late Breaking Research Results From the Alzheimer's Association International Conference 2011
July 25, 2011
- NanoViricides Reports Anti-HIV Efficacy Equivalent to HAART Drug Cocktail Treatment in Animal Study, Successfully Advancing its HIVCide Lead Optimization Program
- Study Results Reveal Link Between Weather Variables and Stroke Incidence
- Medtronic Resolute Drug-Eluting Stent Shows Superiority to Taxus DES in Study of Patients with Coronary Artery Disease
July 26, 2011
- Biogen Idec and Swedish Orphan Biovitrum Present Data on Long-Lasting Recombinant Factor VIII Therapy at International Society on Thrombosis and Haemostasis Meeting
- Interim Data from Phase 2 Study of Combination Regimen Including VX-222 and INCIVEK Suggest Potential to Treat Genotype 1 Hepatitis C in as few as 12 Weeks and No More Than 24 Weeks
- Ligand Partner GlaxoSmithKline Receives Positive Data from Promacta PIII ENABLE1 Study in Hepatitis C-Related Thrombocytopenia
- miRagen Therapeutics and Collaborators Identify Critical Role of microRNA-15 in Cardiomyogenesis
- How Testosterone Protects against Inflammation
- Preliminary Data From Exploratory Phase II Study Demonstrates Significant Activity of Droxidopa in Adult Attention Deficit Hyperactivity Disorder (ADHD)
July 27, 2011
- Publication in BRAIN Highlights Medical Potential of Santhera's Catena in Leber's Hereditary Optic Neuropathy
- Raptor Pharmaceutical Meets Primary Endpoint in Its Phase 3 Clinical Trial of DR Cysteamine for Nephropathic Cystinosis
- Positive ex vivo data on EV-077 in diabetics presented at ISTH conference in Kyoto, Japan
- Amarantus Reports Positive Data in Parkinson's Program
- New Study Says Exposure to High Levels of Stress Throughout Life May Increase Risk of Alzheimer's
- Evergreen Neurologist Co-Authors Key Study on Multiple Sclerosis Treatment Cost
July 28, 2011
- Boston Therapeutics IpoxynTM Data to be Presented Today at Symposium at Massachusetts General Hospital
- Ipsen?s partner Inspiration Biopharmaceuticals announces data from OBI-1 pivotal stage program in Hemophilia at 23rd ISTH congress
- Baxter Presents Preclinical Data at ISTH on Its Investigational Compound BAX 499 for Potential Subcutaneous Hemophilia Therapy and Final Phase I Data on Recombinant von Willebrand Factor
- Inspiration Biopharmaceuticals Announces Data from OBI-1 Pivotal-Stage Program in Hemophilia at 23rd ISTH Congress
- Ablynx (BE) - Initial Observations of Ablynx's Phase II Ttp Programme Presented at Isth Congress
- Bavarian Nordic A/S (DK) - New Article on PROSTVAC® and Other Immunotherapies for Prostate Cancer
